Page 153 - Read Online

Zacharakis et al. Hepatoma Res 2018;4:65 I http://dx.doi.org/10.20517/2394-5079.2018.76 Page 15 of 15

120. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, et al. Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med 2018;379:54-63.
121. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, et al. REACH-2: a randomized, double-blind, placebo-controlled phase 3 study of
ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline
alpha-fetoprotein (AFP) following first-line sorafe. J Clin Oncol 2018;36:4003.
122. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate
040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
123. Maleki Vareki S, Garrigós C, Duran I. Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol 2017;116:116-24.
124. Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, et al. Identification of an immune-specific class of hepatocellular
carcinoma, based on molecular features. Gastroenterology 2017;153:812-26.
125. Wang L, Yao M, Pan LH, Qian Q, Yao DF. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma. Hepatobiliary
Pancreat Dis Int 2015;14:361-6.
126. Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J 2013;280:2471-6.
127. Fu X, Zhu Y, Zheng B, Zou Y, Wang C, et al. KIFC1, a novel potential prognostic factor and therapeutic target in hepatocellular carcinoma.
Int J Oncol 2018;52;1912-22.
128. Hann HW, Wan S, Lai Y, Hann RS, Myers RE, et al. Aspartate aminotransferase to platelet ratio index as a prospective predictor of
hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2015;30:131-8.
129. Tang T, Qiu JL, Li GW, Huang MP, Li Y, et al. Aspartate aminotransferase-to-platelet ratio predicts response to transarterial
chemoembolisation and prognosis in hepatocellular carcinoma patients. Clin Radiol 2018;73:259-65.
130. Suh B, Park S, Shin DW, Yun JM, Yang HK, et al. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic
hepatitis B carriers. Hepatology 2015;61:1261-8.
131. Demir M, Grünewald F, Lang S, Schramm C, Bowe A, et al. Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in
predominantly non-Asian CHB patients. Medicine (Baltimore) 2016; doi: 10.1097/MD.0000000000004602.
132. Toyoda H, Tada T, Tachi Y, Hirai T, Yasuda S, et al. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular
carcinoma after eradication of HCV. Antivir Ther 2017;22:185-93.
133. Choi WM, Lee JH, Ahn H, Cho H, Cho YY, et al. Forns index predicts recurrence and death in patients with hepatitis B-related
hepatocellular carcinoma after curative resection. Liver Int 2015;35:1992-2000.